Search | Clinical Trials Finder

ClinicalTrials.gov public records Last synced Sep 19, 2026, 10:11 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–16 of 16 matching trials from the live ClinicalTrials.gov search.

Local D1 index available.

Filters: Intervention: E2007 (2 mg) Clear all

Conditions: Healthy Participants
Interventions: Perampanel; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 20 Years to 55 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Anaheim, California

Conditions: Epilepsy
Interventions: perampanel; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 1,218 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2014
U.S. locations: 57
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 49 more

Conditions: Central Nervous System
Interventions: perampanel; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 2 Years to 11 Years
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 23
States / cities: Aurora, Colorado • Washington D.C., District of Columbia • Gulf Breeze, Florida + 20 more

Conditions: Lennox-Gastaut Syndrome (LGS)
Interventions: Placebo, Perampanel; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 2 Years and older
Enrollment: 101 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 31
States / cities: Little Rock, Arkansas • Palo Alto, California • Gulf Breeze, Florida + 25 more

Conditions: Diabetic Neuropathy
Interventions: Placebo, E2007 (2 mg), E2007 (4 mg), E2007 (6 mg), E2007 (8 mg); Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 352 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Refractory Partial Seizures
Interventions: E2007 (perampanel), Placebo; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 12 Years to 99 Years
Enrollment: 390 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 60
States / cities: Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 46 more

Conditions: Migraine Prophylaxis
Interventions: E2007, Placebo; Drug · Other
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 206 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 9
States / cities: Oceanside, California • Santa Monica, California • Tampa, Florida + 6 more

Conditions: Epilepsy
Interventions: Perampanel; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 138 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2014
U.S. locations: 12
States / cities: Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 9 more

Conditions: Parkinson's Disease
Interventions: perampanel, placebo; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 30 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 3
States / cities: New Haven, Connecticut • The Woodlands, Texas

Conditions: Neuralgia
Interventions: E2007 (perampanel), Placebo; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 146 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 42
States / cities: Peoria, Arizona • Tucson, Arizona • Little Rock, Arkansas + 38 more

Conditions: Epilepsy
Interventions: Perampanel, Placebo; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 12 Years to 18 Years
Enrollment: 133 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 11
States / cities: Aurora, Colorado • Gulf Breeze, Florida • Orlando, Florida + 8 more

Conditions: Cervical Dystonia
Interventions: Perampanel; Drug
Lead sponsor: University Health Network, Toronto; Other
Eligibility: 18 Years to 65 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 4
States / cities: Atlanta, Georgia • Chicago, Illinois • New York, New York + 1 more

Conditions: Parkinson's Disease
Interventions: 2 mg perampanel, 4 mg perampanel, placebo comparator; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 30 Years and older
Enrollment: 752 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 99
States / cities: Birmingham, Alabama • Huntsville, Alabama • Peoria, Arizona + 82 more

Conditions: Refractory Partial Seizures
Interventions: E2007 (perampanel), Placebo; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 389 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 32
States / cities: Huntsville, Alabama • Phoenix, Arizona • Tucson, Arizona + 17 more

Conditions: Partial Onset Seizures, Secondarily Generalized Seizures, Primary Generalized Tonic-Clonic Seizures
Interventions: Perampanel; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 4 Years and older
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 24
States / cities: Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 20 more

Conditions: Neuralgia
Interventions: E2007; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 262 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Chicago, Illinois

Search by objective public record fields.

Study to Evaluate Bioavailability of a Single 12 mg Dose of Perampanel for Three Intravenous Infusion Durations Relative to a Single 12 mg Perampanel Oral Tablet in Healthy Subjects

Evaluation of the Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures

Pharmacokinetics, Efficacy, and Safety of Perampanel Oral Suspension on Seizure Frequency in Pediatric Subjects Maintained on One to Three Stable Antiepileptic Drugs

Study of Perampanel as Adjunctive Treatment for Inadequately Controlled Seizures Associated With Lennox-Gastaut Syndrome

An Evaluation of the Efficacy and Safety of E2007 in Patients With Painful Diabetic Neuropathy

Evaluating the Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures

Efficacy and Safety Study of E2007 in Migraine Prophylaxis

4-Year Open-Label Extension Phase of the Parallel-Group Study of E2007 in Patients With Refractory Partial Seizures

Assessment of Perampanel (E2007) on Synaptic Dopamine in Mild-moderate PD Patients: A Pilot Study With [^123I]-IBZM SPECT

Dose-Tolerability Titration Study to Evaluate The Efficacy And Safety Of Perampanel (E2007) In Patients With Post-Herpetic Neuralgia (PHN)

A Study With an Open-label Extension Phase to Evaluate the Effect of Perampanel (E2007) on Cognition, Growth, Safety, Tolerability, and Pharmacokinetics in Adolescents

Safety and Tolerability of Perampanel in Cervical Dystonia

Efficacy, Safety, and Tolerability of E2007 in Levodopa Treated Parkinson's Disease Patients With Motor Fluctuations

To Evaluate The Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures

Study to Evaluate the Efficacy and Safety of Perampanel as Monotherapy or First Adjunctive Therapy in Subjects With Partial Onset Seizures With or Without Secondarily Generalized Seizures or With Primary Generalized Tonic-Clonic Seizures

Evaluating E2007 (Perampanel) in Patients With Painful Diabetic Neuropathy (PDN) or Post-Herpetic Neuralgia (PHN)